NEW YORK, Feb 14 – Gemini Genomics said Wednesday it recorded revenues of $72,000 in fiscal third-quarter 2001, compared with zero revenues in the year earlier quarter, as the result of license fees stemming from the company’s osteoporosis diagnostic effort.

Research and development costs for the quarter totaled $3.3 million, compared with $3.0 million, in the year ago quarter. During the quarter, Gemini of Cambridge, UK, accelerated its clinical and research efforts and expanded its research staff.